The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists are a class of newly introduced antidiabetic medications that potentially lower blood glucose by several molecular pathways. DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release. Most patients with diabetes have concurrent hypertension and cardiovascular disorder. If antihyperglycemic agents can attenuate the risk of hypertension and cardiovascular disease, they will amplify their overall beneficial effects. There is conflicting evidence on the cardiovascular benefits of GLP-1R induction in laboratory studies and clinical trials. In this study, we have reviewed the main molecular mechanisms by which GLP-1R induction may modulate the cardiovascular function and the results of cardiovascular outcome clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP1-RA also lower blood pressure; the mechanisms underlying this effect are still under investigation[36] but may be partially attributed to the increase in natriuresis [31].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988 · cited 3×
“Type 1 DM (T1DM) accounts for about 5-10% of all patients with diabetes and results from autoimmune destruction of beta-cells of the pancreas and absolute deficiency of insulin [30].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“NCT01179048 9340 patients with T2DM Liraglutide Reduces the risk of cardiovascular disorders [112]”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“NCT01720446 3297 patients with T2DM Semaglutide Reduces the risk of diabetes-induced cardiovascular problems [116] 5 Journal of Diabetes Research”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“They act as an agonist to GLP-1 receptors and mimic the effects of incretin hormones [14, 15].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“These antihyperglycemic agents activate their specific receptor known as GLP-1R, predominantly located in pancreatic βcell [17].”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159 · cited 2×
“DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release [27, 28].”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“NCT01147250 6068 patients with T2DM Lixisenatide No significant effects on diabetes-induced cardiovascular diseases [114]”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“NCT01144338 14752 patients with T2DM Exenatide No significant effects on diabetes-induced cardiovascular diseases [115]”
Background
Research works printed but not linked: 2
- 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
- S. Hosokawa, 2014, The synergistic effects of incretin-related drugs for the treatment of pulmonary arterial hypertension, American Heart Association, 130, article A13535
Cited by
Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125
“GLP1-RA also lower blood pressure; the mechanisms underlying this effect are still under investigation[36] but may be partially attributed to the increase in natriuresis [31].”
BackgroundCooper, D. H., Ramachandra, R., Ceban, F., Di Vincenzo, J. D., Rhee, T. G., Mansur, R. B., Teopiz, K. M., Gill, H., Ho, R., Cao, B., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.041 · Cited by 79
Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8936865 · Cited by 65
Self-citationNajafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15344 · Cited by 39
Self-citationRecent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 39
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Lecis, D., Prandi, F. R., Barone, L., Belli, M., Sergi, D., Longo, S., Muscoli, S., Romeo, F., Federici, M., Lerakis, S., et al. (2023) · Biomolecules · doi:10.3390/biom13121695 · Cited by 23
“GLP-1RAs stimulate acetylcholine-induced vasodilation and promote nitric oxide release, thus reducing vascular tone with benefits to both systolic and diastolic BP [44].”
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
“GLP-1 receptor agonists increase nitric oxide bioavailability, hence enhancing renal blood flow autoregulation and diminishing oxidative stress in glomerular capillaries (Yaribeygi et al. 2021).”
Jalil, J., Gabrielli, L., Ocaranza, M. P., MacNab, P., Fernández, R., Grassi, B. A., Jofré, P., Verdejo, H., Acevedo, M., Córdova, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084407 · Cited by 28
“In a meta-nalysis including 800 patients with myocardial infarction undergoing angioplasty, GLP-1 RA vs. placebo treatment increased LVEF by 2.5% and reduced the infarct size by 5.3 g (95% CI: − 10.4 to − 0.2) [170].”
InfluentialCooper, D. H., Akbarian, N., Aaron, S. D., Luks, V., & Kendzerska, T. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108197 · Cited by 23
Olukorode, J., Orimoloye, D. A., Nwachukwu, N. O., ONWUZO, C. N., Oloyede, P. O., Fayemi, T., Odunaike, O. S., Ayobami-Ojo, P. S., Divine, N., Alo, D. J., et al. (2024) · Cureus · doi:10.7759/cureus.72080 · Cited by 42
Ferdinand, K. C., Dunn, J. P., Nicolay, C., Sam, F., Blue, E. K., & Wang, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01775-x · Cited by 14
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
Grasset, E., Briand, F., Virgilio, N., Schön, C., Wilhelm, M. G., Cudennec, B., Ravallec, R., Aboubacar, H., Vleminckx, S., Prawitt, J., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4538 · Cited by 9
“…and its comorbidities like fatty liver, dyslipidemia, nephropathy or peripheral neuropathy, particularly since GLP-1 based therapies have shown beneficial effects on these metabolic complications (Przezak, Bielka, and Pawlik 2021; Yaribeygi et al. 2021; Razavi et al. 2022; Mantovani et al. 2021).”
Lin, C., Chen, J., Meyerowitz‐Katz, G., Huang, Y., & Su, P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16191 · Cited by 5
“34 In the context of obesity, where endothelial function is already compromised, the addition of aspirin to GLP-1 RA therapy might negate the beneficial effects on the endothelium, leading to increased vascular inflammation and atherosclerosis progression.”
Toraih, E. A., Alenezy, A. K., Hussein, M. H., Hashmat, S., Mummadi, S., Alrawili, N. F., Abdelmaksoud, A., & Fawzy, M. S. (2025) · Biomedicines · doi:10.3390/biomedicines13051049 · Cited by 8
“(2) GLP-1RAs induce nitric oxide-mediated vasodilation [17], which may perturb the delicate microcirculation of the stria vascularis, a structure that is vital for maintaining endolymphatic potential in the semicircular canals [18].”
Yang, C., Qiu, H., Lv, M., Yang, J., Wu, K., Huang, J., & Jiang, Q. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104531 · Cited by 4
Watts, S. W., Townsend, R. R., & Neubig, R. R. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad121 · Cited by 6
Economos, H., & MacIsaac, R. J. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.109457 · Cited by 5
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Coleman, R. L., Adler, A., Mentz, R. J., Fudim, M., Sattar, N. A., & Holman, R. R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02866-7 · Cited by 3
“GLP-1 RA pleiotropic effects not captured by the conventional risk factors used in UKPDS-OM2 may include anti-inflammatory effects [18], improved endothelial function [19], and beneficial effects on cardiac structure or function [20, 21].”
The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
Gala, D., Botros, F., & Makaryus, A. N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45204 · Cited by 3
Sugiyama, S., Yoshida, A., Kurinami, N., Hieshima, K., Jinnouchi, K., Suzuki, T., MIYAMOTO, F., Kajiwara, K., & Jinnouchi, H. (2025) · Cureus · doi:10.7759/cureus.99998 · Cited by 3
“Possible mechanisms include GLP-1 receptor-mediated activation of endothelial nitric oxide synthase and attenuation of vascular oxidative stress [23-26].”
The Conventional and Alternative Therapeutic Approaches in Arterial Stiffness Management
Randriamboavonjy, J. I., Conti, V., Mazza, I., Ragot, T., Andrianjara, C., Rafatro, H., & Tesse, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020166 · Cited by 2
“Liraglutide also showed an anti-inflammatory effect by reducing Nuclear Factor Kappa-B (NF-κ B) protein expression/activation in the presence of Tumour Necrosis Factor-Alpha (TNF-α ) [77,78].”
Zhang, X., Song, H., Ji, M., Luan, X., Nan, J., & Gao, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1782406 · Cited by 1
Ovariektomize Sıçanlarda Liraglutid’in Kalp Fonksiyonları Üzerine Etkisi
TURAN, İ., Sağlam, C., Erdem, S., & ÖZAÇMAK, H. S. (2022) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1074076 · Cited by 1
Randriamboavonjy, J. I., Rafatro, H., & Andrianjara, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865304
Ferdinand, K. C., Dunn, J., Nicolay, C., Sam, F., Blue, E. K., & Wang, H. (2023) · Figshare · doi:10.6084/m9.figshare.22624691
Raslan, M. A., Nabi, H. A., Dreher, L. A., Osta, S. A., Serra, V. D. S. B., Ayoub, C., Masry, H. E., & Shamoun, F. E. (2026) · Diagnostics · doi:10.3390/diagnostics16111742
“In addition to these direct vascular effects, GLP-1 RAs improve systemic cardiovascular risk factors, including blood pressure, weight, and metabolic parameters [26,27].”
Carlson, K., Kaur, J., Gaber, C. E., Reutrakul, S., & Kim, K. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2726017
Pulmonary hypertension related to sleep-disordered breathing
LACAVERA, M., Asghar, A., Ballard, J., Bandla, M., & Fraidenburg, D. R. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001307
Metadata
- Authors
- Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A.
- Affiliations
- Semnan University of Medical Sciences (IR)
- Shahid Beheshti University (IR)
- University of Hull (GB)
- Medical University of Lodz (PL)
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Yaribeygi, Habib
- Sahebkar, Amirhossein
- ORCID
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2021-06-30
- Volume
- 2021
- Pages
- 1-10
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- PMC
- PMC8263148
- OpenAlex
- W3175947914
- Cited by
- 31
- References
- 118
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 4 · 2023: 8 · 2022: 2 · 2021: 1
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Diabetes Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Baqiyatallah Hospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, DPP-4 inhibitors, blood pressure, hypertension, cardiovascular complications, diabetes mellitus, antidiabetic drugs, cardiovascular outcome trials, glucagon-like peptide-1, insulin secretion, glucagon suppression, antihypertensive effect
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Autonomic Nervous System, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endothelium, Vascular, Heart Rate, Humans, Hypertension, Hypoglycemic Agents, Nitric Oxide, Renin-Angiotensin System, Comorbidity, Treatment Outcome, Oxidative Stress, Diabetes Complications, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
